Mexico
· Delayed Price · Currency is MXN Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of MXN 20.17 billion. The enterprise value is 10.29 billion.
| Market Cap | 20.17B |
| Enterprise Value | 10.29B |
Important Dates
The last earnings date was Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 161.97M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +41.51% |
| Shares Change (QoQ) | +10.85% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 136.60M |
Valuation Ratios
The trailing PE ratio is 2.06.
| PE Ratio | 2.06 |
| Forward PE | n/a |
| PS Ratio | 0.79 |
| PB Ratio | -13.04 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.12, with an EV/FCF ratio of -2.56.
| EV / Earnings | 1.05 |
| EV / Sales | 0.42 |
| EV / EBITDA | 1.12 |
| EV / EBIT | 1.24 |
| EV / FCF | -2.56 |
Financial Position
The company has a current ratio of 2.06
| Current Ratio | 2.06 |
| Quick Ratio | 1.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | 0.49 |
| Debt / FCF | -1.16 |
| Interest Coverage | 19.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 19.97% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 48.55% |
| Revenue Per Employee | 26.94M |
| Profits Per Employee | 10.28M |
| Employee Count | 952 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 40.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +48.72% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +48.72% |
| 50-Day Moving Average | 139.34 |
| 200-Day Moving Average | 190.12 |
| Relative Strength Index (RSI) | 39.67 |
| Average Volume (20 Days) | 1,139 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.65 |
Income Statement
In the last 12 months, Novavax had revenue of MXN 25.65 billion and earned 9.78 billion in profits. Earnings per share was 60.79.
| Revenue | 25.65B |
| Gross Profit | 14.97B |
| Operating Income | 8.64B |
| Pretax Income | 9.98B |
| Net Income | 9.78B |
| EBITDA | 9.56B |
| EBIT | 8.64B |
| Earnings Per Share (EPS) | 60.79 |
Balance Sheet
The company has 14.95 billion in cash and 4.67 billion in debt, giving a net cash position of 10.28 billion.
| Cash & Cash Equivalents | 14.95B |
| Total Debt | 4.67B |
| Net Cash | 10.28B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -1.55B |
| Book Value Per Share | -9.55 |
| Working Capital | 9.11B |
Cash Flow
In the last 12 months, operating cash flow was -3.87 billion and capital expenditures -151.23 million, giving a free cash flow of -4.02 billion.
| Operating Cash Flow | -3.87B |
| Capital Expenditures | -151.23M |
| Free Cash Flow | -4.02B |
| FCF Per Share | n/a |
Margins
Gross margin is 58.37%, with operating and profit margins of 33.69% and 38.14%.
| Gross Margin | 58.37% |
| Operating Margin | 33.69% |
| Pretax Margin | 38.93% |
| Profit Margin | 38.14% |
| EBITDA Margin | 37.25% |
| EBIT Margin | 33.69% |
| FCF Margin | n/a |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.51% |
| Shareholder Yield | -41.51% |
| Earnings Yield | 48.52% |
| FCF Yield | -19.93% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novavax has an Altman Z-Score of -1.71. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.71 |
| Piotroski F-Score | n/a |